Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13005008 | 0.91 | KMT2A (0.44) | KMT2AMAPTHSD11B1HTR2ADRD2 | |
| SCHEMBL11482443 | 0.87 | MAPT (0.44) | KMT2AKDM4EMEN1MAPTHSD11B1 | |
| SCHEMBL22446358 | 0.82 | KMT2A (0.49) | KMT2ATRPM8TRPV1 | |
| SCHEMBL5312276 | 0.80 | KMT2A (0.62) | KMT2ATRPM8TRPV1HTR2B | |
| SCHEMBL31260267 | 0.78 | MAPT (0.47) | KMT2AKDM4EMEN1MAPTHTR2B | |
| SCHEMBL13005016 | 0.77 | DRD2 (0.51) | KMT2AHSD11B1HTR2ADRD2HTR2C | |
| SCHEMBL13791485 | 0.76 | KCNH2 (0.40) | HTR2ADRD2HTR2CKCNH2 | |
| SCHEMBL11471447 | 0.76 | MAPT (0.39) | KMT2AKDM4EMEN1MAPTHTR2B | |
| SCHEMBL13005005 | 0.74 | HTR2A (0.63) | HTR2ADRD2HTR2CKCNH2HRH3 | |
| SCHEMBL619734 | 0.72 | MAPT (0.44) | KMT2AKDM4EMEN1MAPTHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | LIGAND PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | HRH3, HRH4, HRH2 | KMT2A 669/4885KDM4E 2031/4885MEN1 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.